HEALTH.2012.2.1.2-1
HEALTH.2012.2.1.2-1
10 projects · €27,028,170 total EU contribution (project-level) · 66 participating organizations · 15 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€27,028,170
Countries active
Participant organizations by country (headquarters in CORDIS).
- Germany (11)
- France (9)
- Netherlands (7)
- Spain (6)
- UK (6)
- CH (5)
- IE (4)
- US (4)
- HU (3)
- IL (3)
- Italy (3)
- EL (2)
- AT (1)
- CA (1)
- SE (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- AX2 projects · ES
- UT2 projects · DE
- IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE2 projects · UK
- UZH2 projects · CH
- ALU-FR1 projects · DE
- ARIANA1 projects · FR
- Asklepios Medical School1 projects · DE
- BGU1 projects · IL
- BIA1 projects · DE
- BIOMAX INFORMATICS AG1 projects · DE
- BN1 projects · ES
- CELLCALL1 projects · HU
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Identifying correlates of protection to accelerate vaccine trials: systems evaluation of two models of experimentally-induced immunity to malaria SYSMALVAC · 305869 | FP7 | €2,803,652 | €3,635,594 | Details |
Intelligent Surgical Device ISD · 305940 | FP7 | €2,967,103 | €4,252,803 | Details |
Profiling Responders In Antibody Therapies PRIAT · 305309 | FP7 | €2,967,485 | €3,879,647 | Details |
Apoptosis Modelling for Treatment Decisions in Colorectal Cancer APO-DECIDE · 306021 | FP7 | €2,999,482 | €3,896,336 | Details |
Systems prediction of Chronic Lung Allograft Dysfunction SYSCLAD · 305457 | FP7 | €2,999,152 | €3,932,547 | Details |
LSE TECHNOLOGY APPROACH TO GENERATE INNOVATIVE KINASE INHIBITOR DRUGS LSE · 305272 | FP7 | €1,449,681 | €1,883,305 | Details |
Systems biology approaches to cervical pre-cancer and cancer SYSTEMCERV · 306037 | FP7 | €2,368,884 | €3,144,642 | Details |
WINTHERapeutics: development of a systems biology method to predict efficacy of cancer drugs to optimize individualized therapeutic decision and improve clinical outcome for cancer patients WINTHER · 306125 | FP7 | €2,998,355 | €4,229,837 | Details |
A novel drug discovery method based on systems biology: combination therapy and biomarkers for Multiple Sclerosis COMBIMS · 305397 | FP7 | €2,509,680 | €3,273,834 | Details |
Development of COMBInatorial BIOmarkers for subclinical atherosclerosis COMBI-BIO · 305422 | FP7 | €2,964,696 | €3,878,715 | Details |